Achieving High Sensitivity and Concordance for CGP from “Liquid Biopsy” Specimens
Wednesday, November 15, 2023
11:00 AM – 11:50 AM MST
Comprehensive Genomic Profiling (CGP) of whole blood “liquid biopsy” specimens from cancer patients is being performed in increasing numbers when tumor tissue is inaccessible or unavailable. The accuracy and sensitivity of circulating tumor DNA (ctDNA) assays vary greatly. Consequently, a rigorous validation including comparisons with matched tissue is critical in establishing clinical utility.
We will discuss important considerations when establishing a ctDNA CGP assay to ensure high sensitivity and concordance and share implementation challenges and proposed solutions experienced in a community-based, Integrated Network Cancer Program. We will also highlight the benefits of in-house CGP testing for both tissue and liquid.